Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
European Journal of Cancer Care|October 25, 2017
Antiresorptive treatment-associated ONJEvangelos Eleutherakis-Papaiakovou, Aristotelis Bamias
Journal of Oncology|May 16, 2020
Efficacy of Panobinostat for the Treatment of Multiple MyelomaEvangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Efstathios Kastritis, et al.
Expert Review of Anticancer Therapy|November 5, 2019
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myelomaEvangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Rituximab-based treatments in Waldenström's macroglobulinemiaMeletios A Dimopoulos, Efstathios Kastritis, Maria Roussou, et al.
American Journal of Hematology|June 13, 2013
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimensTina Bagratuni, Efstathios Kastritis, Marianna Politou, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 23, 2020
Response of an oncology unit in the midst of the COVID-19 outbreakMichalis Liontos, Efstathios Kastritis, Magdalini Migkou, et al.
Leukemia & Lymphoma|June 13, 2017
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapyEfstathios Kastritis, Pelagia Melea, Tina Bagratuni, et al.
Blood Cancer Journal|May 12, 2018
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myelomaEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Dimitrios Christoulas, et al.
American Journal of Hematology|May 9, 2012
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agentsAnna Tasidou, Maria Roussou, Evangelos Terpos, et al.
Leukemia & Lymphoma|February 27, 2016
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myelomaFlora Zagouri, Maria Roussou, Efstathios Kastritis, et al.
Pageof 9